A
Anthony Boral
Researcher at Novartis
Publications - 16
Citations - 2415
Anthony Boral is an academic researcher from Novartis. The author has contributed to research in topics: Ceritinib & Anaplastic lymphoma kinase. The author has an hindex of 12, co-authored 16 publications receiving 2191 citations.
Papers
More filters
Journal ArticleDOI
Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw,Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Martin Schuler,Geoffrey Liu,Armando Santoro,Yvonne Y. Lau,Meredith Goldwasser,Anthony Boral,Jeffrey A. Engelman +21 more
TL;DR: Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK.
Journal ArticleDOI
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Jun Liu,Shifeng Pan,Mindy H. Hsieh,Nicholas Ng,Fangxian Sun,Tao Wang,Shailaja Kasibhatla,Alwin Schuller,Allen G. Li,Dai Cheng,Jie Li,Celin Tompkins,Anne Marie Pferdekamper,Auzon Steffy,Jane Cheng,Colleen Kowal,Van Phung,Gui-Rong Guo,Yan Wang,Martin P. Graham,Shannon Flynn,J. Chad Brenner,Chun Li,M. Cristina Villarroel,Peter G. Schultz,Xu Wu,Peter McNamara,William R. Sellers,Lilli Petruzzelli,Anthony Boral,H. Martin Seidel,Margaret E. McLaughlin,Jianwei Che,Thomas E. Carey,Gary J. Vanasse,Jennifer L. Harris +35 more
TL;DR: LGK974 is potent and efficacious in multiple tumor models at well-tolerated doses in vivo, including murine and rat mechanistic breast cancer models driven by MMTV–Wnt1 and a human head and neck squamous cell carcinoma model (HN30).
Journal ArticleDOI
Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.
Dong Wan Kim,Ranee Mehra,Daniel Shao-Weng Tan,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Gregory J. Riely,Benjamin Solomon,Juergen Wolf,Michael Thomas,Martin Schuler,Geoffrey Liu,Armando Santoro,Margarida Geraldes,Anthony Boral,A. Yovine,Alice T. Shaw +19 more
TL;DR: Ceritinib (LDK378) is a novel ALK inhibitor (ALKi) more potent than CRZ in enzymatic and cell-busting activities, and may be a viable alternative to crizotinib in patients with NSCLC.
Journal ArticleDOI
Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.
Alice T. Shaw,Ranee Mehra,Dong Wan Kim,Enriqueta Felip,Laura Q.M. Chow,D. Ross Camidge,Daniel Shao-Weng Tan,Johan Vansteenkiste,Sunil Sharma,Tommaso De Pas,Juergen Wolf,Ryohei Katayama,Yi-Yang Yvonne Lau,Meredith Goldwasser,Anthony Boral,Jeffrey A. Engelman +15 more
TL;DR: This data indicates that conventional chemotherapy for lung cancers harboring anaplastic lymphoma kinase (ALK) gene rearrangements are sensitive to the tyrosine kinase inhibitor (TKI) crizotinib (CRZ), but invariably develop resistance to these drugs.
Journal ArticleDOI
Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
Makoto Nishio,Haruyasu Murakami,Atsushi Horiike,Toshiaki Takahashi,Fumihiko Hirai,Naoko Suenaga,Takeshi Tajima,Kota Tokushige,Masami Ishii,Anthony Boral,Matthew Robson,Takashi Seto +11 more
TL;DR: The maximum-tolerated dose, safety, pharmacokinetics (PK), and antitumor activity of ceritinib, a novel ALK inhibitor (ALKi), in Japanese patients with ALK-rearranged malignancies was 750 mg once daily inJapanese patients.